Richard W.  Pascoe net worth and biography

Richard Pascoe Biography and Net Worth

Chairman of Zevra Therapeutics
Mr. Pascoe has served as a director of KemPharm since January 2014 and as KemPharm’s executive chairman since November 2021. He served as lead independent director at KemPharm from November 2014 to November 2021. Mr. Pascoe served as the president and chief executive officer of Histogen Inc, a biologics company, from January 2019 to November 2021. From March 2013 to January 2019, Mr. Pascoe was the chief executive officer and a director of Apricus Biosciences, Inc., a specialty pharmaceutical company. From August 2008 to March 2013, Mr. Pascoe was the president and chief executive officer and a director of Pernix Sleep, Inc. (formerly known as Somaxon Pharmaceuticals, Inc.), a specialty pharmaceutical company. Prior to Pernix, from 2005 to 2008, Mr. Pascoe worked for ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company, where he was most recently senior vice president and chief operating officer. Mr. Pascoe also serves as a director of Seelos Therapeutics, Inc, a specialty pharmaceutical company. Mr. Pascoe received his B.S. degree from the United States Military Academy at West Point.

What is Richard W. Pascoe's net worth?

The estimated net worth of Richard W. Pascoe is at least $0.00 as of March 9th, 2023. Mr. Pascoe owns 29,973 shares of Zevra Therapeutics stock worth more than $0 as of March 28th. This net worth estimate does not reflect any other assets that Mr. Pascoe may own. Learn More about Richard W. Pascoe's net worth.

How do I contact Richard W. Pascoe?

The corporate mailing address for Mr. Pascoe and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on Richard W. Pascoe's contact information.

Has Richard W. Pascoe been buying or selling shares of Zevra Therapeutics?

Richard W. Pascoe has not been actively trading shares of Zevra Therapeutics during the last quarter. Most recently, on Friday, January 13th, Richard W. Pascoe bought 9,500 shares of Zevra Therapeutics stock. The stock was acquired at an average cost of $5.44 per share, with a total value of $51,680.00. Following the completion of the transaction, the chief executive officer now directly owns 19,973 shares of the company's stock, valued at $108,653.12. Learn More on Richard W. Pascoe's trading history.

Who are Zevra Therapeutics' active insiders?

Zevra Therapeutics' insider roster includes R. Clifton (CFO), Travis Mickle (CEO), Richard Pascoe (Chairman), and David Tierney (Director). Learn More on Zevra Therapeutics' active insiders.

Richard W. Pascoe Insider Trading History at Zevra Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/13/2023Buy9,500$5.44$51,680.0019,973View SEC Filing Icon  
5/18/2022Buy5,000$4.92$24,600.008,285View SEC Filing Icon  
11/30/2021Buy1,500$7.88$11,820.00View SEC Filing Icon  
8/18/2020Buy10,000$0.64$6,400.00
See Full Table

Richard W. Pascoe Buying and Selling Activity at Zevra Therapeutics

This chart shows Richard W Pascoe's buying and selling at Zevra Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zevra Therapeutics Company Overview

Zevra Therapeutics logo
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $5.51
Low: $4.48
High: $6.27

2 Week Range

Now: N/A

Volume

64,100 shs

Average Volume

189,500 shs

Market Capitalization

$200.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16